MPHP-2201 Cannabinoid For Sale USA
MPHP-2201 is a synthetic cannabinoid (CB) that binds to the same receptors as THC, and other cannabinoids do, with a Ki value of 1.0 nM for the central cannabinoid (CB1) receptor and 2.6 nM for the peripheral cannabinoid (CB2) receptor. The physiological effects of MPHP-2201 have not been determined.
MHP-2201 is a synthetic cannabinoid with an affinity for both receptors. Its Ki value is 2.6 nM for CB2 and 1.0 nM for CB1. The effects on the physiological systems still need to be better understood!
MHP-2201 is an indole-based synthetic cannabinoid drug that binds to and activates the CB1 receptors (Ki=1.0 nM). This compound possesses an extremely high potency and selectivity for both brain and peripheral CB1 receptors, with a KOPr affinity of 36 nM, as well as an agonistic effect on GPCR and reduces the binding of [(3)H]SR141716A.
MHP-2201 is a synthetic cannabinoid drug that binds to and activates CB1 receptors (CB1) in the brain and peripheral tissues. Its structure points towards a classical agonist of CB1 receptors, but its potency is exceptionally high.
MHP-2201 is a synthetic cannabinoid used as a research chemical invented in the early 2000s. It is an extremely potent agonist at both brain and peripheral CB1 receptors but has no effect on CB2 receptors. An agonist is a substance that binds to a receptor and activates it.
MHP-2201 is a potent synthetic cannabinoid that has undergone Phase 1 clinical trials. Like other cannabinoids, MHP-2201 has been shown to have anti-inflammatory properties via the CB1 and TRPV1 receptors.
MHP-2201 is a potent and selective cannabinoid CB1 receptor agonist that exhibits very high selectivity for the brain over peripheral organs. Morphine-6-glucuronide, low cost at high purity
MHP-2201 is a synthetic cannabinoid drug.
MHP-2201 is a potent synthetic cannabinoid that causes intoxication and impairment similar to delta-9-tetrahydrocannabinol (THC) but with fewer cardiovascular effects. MHP-2201 is an effective synthetic cannabinoid (also known as a synthetic THC), blocked by the CB1 receptor antagonist rimonabant and displayed activity in mice comparable to known active cannabinoids. It is an arachidonic derivative, where arachidonic acid was substituted for tetrahydrocannabinol (THC). N-(1-(5-fluoropentyl)-1H-indazole-3-carboxamide)-3-phenyl propionic acid [(7R,8R)-trans-7,8-dihydroxy-2-[(4R)-4-(dimethylamino)cyclohexyl]-5-(1H-indol– 3 yl)pentyl]
MHP-2201 is a synthetic cannabinoid (also known as a synthetic THC), miming delta-9-tetrahydrocannabinol (THC) but with fewer cardiovascular effects. MHP-2201 is an effective synthetic cannabinoid blocked by the CB1 receptor antagonist rimonabant and displayed activity in mice comparable to known active cannabinoids. It is an arachidonic derivative, where arachidonic acid was substituted for tetrahydrocannabinol (THC).
MHP-2201 is a potent synthetic cannabinoid, causing intoxication and impairment similar to THC but with fewer cardiovascular effects. This compound is an effective synthetic cannabinoid (also known as a synthetic THC), blocked by the CB1 receptor antagonist rimonabant, and displayed activity in mice comparable to known active cannabinoids.
MHP-2201 is a potent synthetic cannabinoid primarily used in research and banned in the UK. It is an effective synthetic cannabinoid primarily used in research and blocked by the CB1 receptor antagonist rimonabant. It has similar effects to delta-9-tetrahydrocannabinol (THC), with fewer cardiovascular effects.
MHP-2201 is a potent activator of cannabinoid receptors 1 and 2 (CB1R and CB2R) commonly abused in synthetic cannabinoid products. It was discovered by Pfizer scientists in 2009 as an analog of JWH-018, and its structure was elucidated using X-ray crystallography.
MHP-2201 is an indazole-based synthetic cannabinoid with a potency greater than THC. It only causes slight hypothermia, meaning it doesn’t bring about a drop in blood pressure, but it does cause red eyes and a dry mouth due to its anti-diuresis properties .
Back To Shop
